Neurofibroma, Plexiform - 25 Studies Found
Recruiting |
: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations : Cancer : 2014-04-24 :
|
Completed |
: PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma :
|
Recruiting |
: AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors :
: Drug: AZD6244 AZD6244 orally every 12 hours on continuous daily schedule for cycles of 28 days until una |
Active, not recruiting |
: Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas :
: 2010-06-08 : Drug: Gleevec Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with |
Completed |
: Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas : Neurofibromatosis : 2012-08-22 : Drug: Gleevec Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects |